Skip to main content
Caplight Logo









BreezeBio

BreezeBio

Private
South San Francisco, CaliforniaHealthcare & Life Scienceshttps://breezebio.com/

Last Round

Series B

Feb 25, 2026

Total Funding Raised

$153.55M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

BreezeBio is a biotechnology company that develops precision genetic medicines for autoimmune diseases and oncology using its proprietary NanoGalaxy nanoparticle delivery platform.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting

AI Layer

Non-AI

Keywords

genetic medicine deliverygene therapy deliverypolymer nanoparticlesdrug delivery platformnanoparticle deliverynon-viral deliverynon-lipid deliverydrug delivery vehiclegenetic medicinesgene editor deliverygene therapyCRISPR deliveryRNA deliverytargeted drug deliveryextra-hepatic deliverybiotech partnershipsautoimmune disease therapyneuromuscular disease therapy

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

BreezeBio Comparables

Compare BreezeBio with similar companies based on industry and business-model similarity.

BreezeBio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Code Biotherapeutics
88%
ViaNautis Bio
84%
Hopewell Therapeutics
82%

BreezeBio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BFeb 25, 2026
Series BNov 20, 2024
Series A ExtensionJan 23, 2024
GrantDec 13, 2023
Series ASep 23, 2021
Seed
Dec 11, 2018

Key People

Founding team and executive leadership

Kunwoo Lee

Chief Executive Officer Co-founder

Founding Team

Jeff Kang

Chief Financial Officer

Executive Team

BreezeBio Investors

Notable investors and investment history

BreezeBio investors
InvestorRounds
SV InvestmentSeries B
DSC InvestmentSeries B
Top Harvest CapitalSeries B
K2 Investment PartnersSeries A Extension
IMM InvestmentSeries A, Series A Extension
KB InvestmentSeries A, Series A Extension
DAYLI PartnersSeries A Extension, Series B, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 2, 2026

    Focus on IND-enabling studies for genetic medicine delivery platform.

  • Feb 25, 2026

    $60M round led by DSC Investment and Yuanta Investment.

BreezeBio Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

BreezeBio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about BreezeBio's valuation, stock price, and market status.

Firmographic Details

HeadquartersSouth San Francisco, California
Employee Range64
Year Founded2016
Last FundingFeb 25, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?